Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What is the Anticipated CAGR of the Female Infertility Market, and What Factors Will Drive It?

The market for female infertility has seen a consistent expansion in recent years. The valuation is expected to rise from $1.79 billion in 2024 to $1.87 billion in 2025, registering a compound annual growth rate (CAGR) of 4.5%. The augmentation during the historical period can be credited to a range of factors including the emerging trend of women postponing having children, lifestyle alterations, proliferating government initiatives, an increasing elderly population, and the surge in assisted reproductive technology (ART) practices.

The market size of female infertility is predicted to undergo consistent expansion in the upcoming years. By 2029, it is expected to reach $2.19 billion, with a compound annual growth rate (CAGR) of 4.1%. The growth in this forecast period is attributable to an enhanced understanding of fertility problems, an uptick in instances of polycystic ovary syndrome, an increase in cases of uterine abnormalities, a surge in occurrences of genetic disorders, and rising obesity. Key trends observed in this forecast period include advancements in preimplantation genetic screening, technological progression, emerging diagnostic technologies, fertility retention, and telemedicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

Which Factors and External Forces Are Driving Demand in the Female Infertility Market?

The upward trend in infertility is projected to fuel the expansion of the female infertility market in the future. Infertility is defined as the inability to conceive following 12 months of regular, unprotected sexual activity. This escalating problem is prompted by various factors including delaying childbearing, alterations in lifestyle, environmental contaminants, rising obesity levels, and augmented stress levels. Treatment for female infertility is essential to address and manage the root causes like medical, hormonal, or structural problems that hinder fertility, thereby improving the likelihood of conception and averting permanent infertility. For example, in July 2024, the Human Fertilization and Embryology Authority, a UK-based independent public body of the Department of Health and Social Care, reported that licensed fertility clinics across the UK conducted around 77,000 fresh and frozen embryo transfer IVF cycles for 52,500 patients in 2022. Over 90% of these patients pursued treatment with a partner, involving nearly 100,000 individuals. Therefore, the rise in infertility prevalence underpins the growth of the female infertility market.

Which Segments in the Female Infertility Offer the Most Growth?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20787&type=smp

What Are the Fastest-Growing Geographies in the Female Infertility Market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Female Infertility Market?

Leading businesses in the female infertility market are prioritizing the creation of novel products such as non-invasive diagnostic tests to establish their prominence within the sector. Non-invasive diagnostic tests are medical procedures that allow for disease or condition detection without the need for surgical intervention or bodily penetration. For example, in August 2024, Heranova Lifesciences, a biotech firm headquartered in the US, initiated an early access scheme for HerResolve, a non-invasive diagnostic examination for endometriosis – a condition impacting around 200 million women globally. This disease often results in infertility, pain, and bleeding. Unfortunately, a majority of women receive a definitive diagnosis only 7-10 years after initial symptom presentation, a delay primarily attributable to symptom inconsistency and the invasive nature of the most trusted diagnostic approach, exploratory laparoscopic surgery. HerResolve aims to considerably lessen this diagnostic time gap, transitioning it from years to mere months, thereby enhancing both patient and healthcare results. Its significant goal is to media this lengthy process to ensure improved patient care and outcome.

View the full report here:

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

What Are the Key Elements That Define the Female Infertility Market?

Female infertility is defined as the inability of a woman to conceive after 12 months of regular, unprotected sexual intercourse (or 6 months for women aged 35 or older) or the inability to carry a pregnancy to term. It is a complex condition resulting from various factors affecting the reproductive system.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model